IN2013MN00758A - - Google Patents

Download PDF

Info

Publication number
IN2013MN00758A
IN2013MN00758A IN758MUN2013A IN2013MN00758A IN 2013MN00758 A IN2013MN00758 A IN 2013MN00758A IN 758MUN2013 A IN758MUN2013 A IN 758MUN2013A IN 2013MN00758 A IN2013MN00758 A IN 2013MN00758A
Authority
IN
India
Prior art keywords
therapeutic agent
devices
implants
antibodies
months
Prior art date
Application number
Other languages
English (en)
Inventor
Paul Ashton
Leigh T Canham
Christian Barnett
Original Assignee
Psivida Inc
Psimedica Ltd
Psivida Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psivida Inc, Psimedica Ltd, Psivida Corp filed Critical Psivida Inc
Publication of IN2013MN00758A publication Critical patent/IN2013MN00758A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN758MUN2013 2010-11-01 2011-11-01 IN2013MN00758A (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40893410P 2010-11-01 2010-11-01
US201161470299P 2011-03-31 2011-03-31
PCT/US2011/058774 WO2012061377A1 (en) 2010-11-01 2011-11-01 Bioerodible silicon-based devices for delivery of therapeutic agents

Publications (1)

Publication Number Publication Date
IN2013MN00758A true IN2013MN00758A (enExample) 2015-06-12

Family

ID=46024803

Family Applications (1)

Application Number Title Priority Date Filing Date
IN758MUN2013 IN2013MN00758A (enExample) 2010-11-01 2011-11-01

Country Status (11)

Country Link
US (3) US9333173B2 (enExample)
EP (1) EP2635255B1 (enExample)
JP (2) JP6026424B2 (enExample)
CN (4) CN104586742A (enExample)
AU (2) AU2011323524B2 (enExample)
CA (1) CA2816576C (enExample)
HK (3) HK1210048A1 (enExample)
IN (1) IN2013MN00758A (enExample)
RU (1) RU2640918C2 (enExample)
TW (1) TWI615150B (enExample)
WO (1) WO2012061377A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
EP2427179A4 (en) 2009-05-04 2013-09-11 Psivida Inc POROUS SILICON MEDICATION ELUTING PARTICLES
IN2013MN00758A (enExample) 2010-11-01 2015-06-12 Psivida Inc
US20140271764A1 (en) * 2013-03-12 2014-09-18 Psivida Us, Inc. Bioerodible Silicon-Based Delivery Vehicles for Delivery of Therapeutic Agents
EP2968882B1 (en) * 2013-03-12 2021-05-19 EyePoint Pharmaceuticals US, Inc. Drug delivery device comprising silicon-based carrier particles
EP2968571A4 (en) 2013-03-15 2016-09-07 Psivida Inc BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS
US20160075776A1 (en) * 2014-09-16 2016-03-17 Paul Ashton Compositions and Methods for Controlled Release of Agents
JP6883257B2 (ja) * 2017-05-16 2021-06-09 株式会社豊田中央研究所 還元反応用固体触媒
AU2019290582A1 (en) 2018-06-19 2021-01-28 Cella Therapeutics, Llc Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor-alpha (TNF-alpha) or TNF receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease
AU2019288296B2 (en) 2018-06-19 2022-11-24 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a CNP compound, an NPR-B compound, a Tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
JP2021535739A (ja) 2018-08-27 2021-12-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 下流精製でのラマン分光法の使用
US12016958B2 (en) * 2021-02-26 2024-06-25 Nano Targeting & Therapy Biopharma Inc. Method for delivering an agent to posterior segment of an eye and uses thereof
TWI803092B (zh) * 2021-04-01 2023-05-21 逢甲大學 具負載與釋放活性成分的奈米粒子、其製造方法與眼用裝置之應用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3832458A (en) 1971-12-06 1974-08-27 River C Foundation Hydrophilic silicone composition and method
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
US3919723A (en) 1974-05-20 1975-11-18 Friedrichsfeld Gmbh Bone shaft or bone joint prosthesis and process
US3919060A (en) 1974-06-14 1975-11-11 Ibm Method of fabricating semiconductor device embodying dielectric isolation
DE3214667C2 (de) 1982-04-21 1985-07-18 Akzo Gmbh, 5600 Wuppertal Zusammengesetzter Körper für die Langzeitabgabe von Wirkstoffen
JPS59101145A (ja) 1982-11-30 1984-06-11 日本特殊陶業株式会社 薬液含浸多孔質セラミツクス
JPS59131346A (ja) 1983-01-17 1984-07-28 日本特殊陶業株式会社 薬液含浸多孔質セラミツクスの製造法
DE3423667A1 (de) 1984-05-08 1985-11-28 Rüdiger Dipl.-Ing. 5204 Lohmar Scheunemann Implantat fuer knochen- und zahnwurzelersatz mit spezieller uebergangsstruktur zwischen knochen und implantatkern und knochenseitig ganz oder teilweise resorbierbarer matrix
GB8422876D0 (en) 1984-09-11 1984-10-17 Secr Defence Silicon implant devices
US4608048A (en) 1984-12-06 1986-08-26 Alza Corporation Dispensing device with drug delivery patterns
US5057082A (en) 1988-11-04 1991-10-15 Plastic Injectors, Inc. Trocar assembly
DK0463061T3 (da) 1989-03-17 1993-07-12 Pitman Moore Inc Controlled-release tilførselsindretning til afgivelse af makromolekylære proteiner
US5167625A (en) 1990-10-09 1992-12-01 Sarcos Group Multiple vesicle implantable drug delivery system
IL105396A (en) * 1992-04-30 1998-02-22 Takeda Chemical Industries Ltd Prefilled syringe
US5366454A (en) 1993-03-17 1994-11-22 La Corporation De L'ecole Polytechnique Implantable medication dispensing device
US5370630A (en) 1993-11-12 1994-12-06 Smidebush; Michael J. Device for injection of fluidic materials into body tissue
US5489266A (en) * 1994-01-25 1996-02-06 Becton, Dickinson And Company Syringe assembly and method for lyophilizing and reconstituting injectable medication
US5558071A (en) 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
US5591453A (en) 1994-07-27 1997-01-07 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
US5817327A (en) 1994-07-27 1998-10-06 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
US5665114A (en) 1994-08-12 1997-09-09 Meadox Medicals, Inc. Tubular expanded polytetrafluoroethylene implantable prostheses
US5792099A (en) 1995-02-14 1998-08-11 Decamp; Dennis Syringe and cannula for insertion of viscoelastic material into an eye and method of using same
WO1996031197A1 (en) 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
US6096344A (en) 1995-07-28 2000-08-01 Advanced Polymer Systems, Inc. Bioerodible porous compositions
GB9611437D0 (en) 1995-08-03 1996-08-07 Secr Defence Biomaterial
US5665428A (en) 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
DE19608423A1 (de) 1996-03-05 1997-09-11 Merck Patent Gmbh Implantate mit phasenweiser Arzneistoffabgabe
FR2749169B1 (fr) * 1996-06-04 1998-08-21 Delab Procede pour constituer une preparation injectable et dispositif pour la mise en oeuvre de ce procede
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US7070590B1 (en) 1996-07-02 2006-07-04 Massachusetts Institute Of Technology Microchip drug delivery devices
US5922299A (en) 1996-11-26 1999-07-13 Battelle Memorial Institute Mesoporous-silica films, fibers, and powders by evaporation
JP3217286B2 (ja) * 1996-12-19 2001-10-09 科学技術振興事業団 Ｄｎａ固定化複合体
US6696258B1 (en) 1998-01-20 2004-02-24 Drexel University Mesoporous materials and methods of making the same
AU2460099A (en) 1998-01-20 1999-08-02 Drexel University Mesoporous materials and methods of making the same
US6060036A (en) 1998-02-09 2000-05-09 Implant Sciences Corporation Radioactive seed implants
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
GB9815819D0 (en) 1998-07-22 1998-09-16 Secr Defence Transferring materials into cells and a microneedle array
ATE306250T1 (de) 1998-12-23 2005-10-15 Alza Corp Dosierungsformen, die poröse partikel enthalten
WO2000040089A1 (en) * 1999-01-05 2000-07-13 Massachusetts Eye And Ear Infirmary Targeted transscleral controlled release drug delivery to the retina and choroid
HK1042051A1 (zh) 1999-08-16 2002-08-02 Henceforth Hibernia Inc. 包含有催化生物拟态固形物的治疗及预防用药物，以及其制备和使用方法
GB9924334D0 (en) 1999-10-15 1999-12-15 Secr Defence Pharmaceutical products and methods of fabrication therefor
HK1045110A1 (zh) 1999-10-18 2002-11-15 Ferx Incorporated 磁性目标载体
SE9903958D0 (sv) 1999-11-02 1999-11-02 Boerje Sellergren Porous materials for selective binding or transport of molecular guests
US6521284B1 (en) 1999-11-03 2003-02-18 Scimed Life Systems, Inc. Process for impregnating a porous material with a cross-linkable composition
AUPQ573300A0 (en) 2000-02-21 2000-03-16 Australian Nuclear Science & Technology Organisation Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
MXPA02008355A (es) 2000-02-28 2002-12-13 Aventis Pharma Sa Composicion que comprende camptotecina y derivado de pirimidina para tratamiento del cancer.
IL134830A0 (en) 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
CN1487836A (zh) 2000-03-14 2004-04-07 埃米林药品公司 胰高糖素样肽1(7-36)对胃窦幽门十二指肠能动性的影响
GB0008494D0 (en) 2000-04-07 2000-05-24 Secr Defence Microprojectile delivery system
GB2365769A (en) 2000-08-18 2002-02-27 Secr Defence Skin preparations containing silicon
GB0104383D0 (en) 2001-02-22 2001-04-11 Psimedica Ltd Cancer Treatment
US6973718B2 (en) 2001-05-30 2005-12-13 Microchips, Inc. Methods for conformal coating and sealing microchip reservoir devices
WO2004018360A1 (en) 2002-08-23 2004-03-04 Mcmaster University Methods and compounds for controlling the morphology and shrinkage of silica derived from polyol-modified silanes
ES2400852T3 (es) 2002-09-18 2013-04-12 Allergan Inc. Aparato para el aporte de implantes oculares
US7713778B2 (en) 2003-02-13 2010-05-11 Univ California Nanostructured casting of organic and bio-polymers in porous silicon templates
US7433811B2 (en) 2003-05-06 2008-10-07 The Regents Of The University Of California Direct patterning of silicon by photoelectrochemical etching
US7563451B2 (en) 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
WO2005042023A1 (en) 2003-10-21 2005-05-12 Psimedica Limited Composite material comprising a porous semiconductor impregnated with an organic substance
GB0324483D0 (en) 2003-10-21 2003-11-19 Psi Medica Ltd Composite material
US20050181049A1 (en) 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
US7448867B2 (en) 2004-09-17 2008-11-11 Ormco Corporation Medical treatment apparatus
WO2006039333A1 (en) 2004-09-30 2006-04-13 Bausch & Lomb Incorporated Ophthalmic drug release device for multiple drug release
WO2006037160A1 (en) * 2004-10-05 2006-04-13 The University Of Melbourne Porous polyelectrolyte materials
EP3381446A1 (en) 2004-10-29 2018-10-03 The Regents of The University of California Porous photonic crystals for drug delivery to the eye
JP4977475B2 (ja) 2004-12-21 2012-07-18 日本電気株式会社 フィルム外装電気デバイス用ケース
JP2007091716A (ja) 2005-08-29 2007-04-12 Kuraray Co Ltd 水中薬剤徐放性微粒子及びその製造方法
GB0526332D0 (en) 2005-12-23 2006-02-01 Psimedica Ltd Pharmaceutical product
JP2009529888A (ja) * 2006-03-14 2009-08-27 ユニバーシティ オブ ロチェスター 超薄多孔質メンブレンを有する細胞培養装置およびその使用
NZ571758A (en) 2006-03-31 2012-06-29 Quadra Logic Tech Inc A drug insert surrounded by a sheath to expose a polymer containing a drug to surrounding tissues or an eye
JP4984644B2 (ja) * 2006-05-19 2012-07-25 株式会社ジェイ・エム・エス 注射装置
US9248121B2 (en) * 2006-08-21 2016-02-02 Abbott Laboratories Medical devices for controlled drug release
KR101329658B1 (ko) 2006-09-25 2013-11-14 아처 다니엘 미드랜드 캄파니 초흡수성 표면처리된 카르복시알킬화 다당류 및 그 제조방법
JP5141948B2 (ja) * 2007-07-09 2013-02-13 株式会社豊田中央研究所 バイモダルな細孔構造を有する球状シリカ系メソ多孔体及びその製造方法
KR20160021307A (ko) * 2007-07-10 2016-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
US20130084243A1 (en) 2010-01-27 2013-04-04 Liliane Goetsch Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
CN104224703A (zh) 2008-09-25 2014-12-24 赛福伦公司 苯达莫司汀的液体配制品
GB0817936D0 (en) * 2008-09-30 2008-11-05 Intrinsiq Materials Global Ltd Porous materials
GB0817938D0 (en) 2008-09-30 2008-11-05 Intrinsiq Materials Global Ltd Cosmetic formulations
JP5369725B2 (ja) 2009-01-30 2013-12-18 株式会社ニコン 撮像装置
US20120045515A1 (en) * 2009-02-04 2012-02-23 Ye Liu Hollow silica particle with a polymer thereon
US20110300222A1 (en) 2009-02-20 2011-12-08 The Regents Of The University Of California Luminescent porous silicon nanoparticles, methods of making and using same
US20100247607A1 (en) 2009-03-26 2010-09-30 Psivida Us, Inc. Implantable formulations of bisphosphonic acids
JP5382700B2 (ja) 2009-03-27 2014-01-08 独立行政法人産業技術総合研究所 ロッド状多孔質シリカ粒子
EP2427179A4 (en) 2009-05-04 2013-09-11 Psivida Inc POROUS SILICON MEDICATION ELUTING PARTICLES
US20110028412A1 (en) 2009-08-03 2011-02-03 Cappellos, Inc. Herbal enhanced analgesic formulations
DE102010008982A1 (de) 2010-02-24 2011-08-25 Bayer Innovation GmbH, 40225 Siliciumhaltiges, biologisch degradierbares Material zur anti-inflammatorischen Therapie
GB201017048D0 (en) 2010-10-08 2010-11-24 Ucl Business Plc Composition
IN2013MN00758A (enExample) 2010-11-01 2015-06-12 Psivida Inc
WO2012088306A2 (en) 2010-12-22 2012-06-28 Psivida Us, Inc. Two-piece injectable drug delivery device with heat-cured seal
US20120207682A1 (en) 2011-02-11 2012-08-16 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics
JP2014510590A (ja) 2011-03-31 2014-05-01 ガルデルマ・リサーチ・アンド・デベロップメント フィラー製品および少なくとも１つの生体吸収性および生分解性シリカベースの材料を含む組成物
WO2013030679A2 (en) 2011-08-29 2013-03-07 Qlt Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
JP6333280B2 (ja) 2012-11-21 2018-05-30 アジオス ファーマシューティカルズ， インコーポレイテッド グルタミナーゼ阻害剤およびその使用方法
US20140271764A1 (en) 2013-03-12 2014-09-18 Psivida Us, Inc. Bioerodible Silicon-Based Delivery Vehicles for Delivery of Therapeutic Agents
US10517844B2 (en) 2014-11-13 2019-12-31 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications

Also Published As

Publication number Publication date
AU2011323524A1 (en) 2013-05-23
US9808421B2 (en) 2017-11-07
JP2016121173A (ja) 2016-07-07
AU2011323524B2 (en) 2016-12-08
RU2013119438A (ru) 2014-12-10
HK1210048A1 (en) 2016-04-15
EP2635255A4 (en) 2016-11-09
WO2012061377A1 (en) 2012-05-10
HK1210416A1 (en) 2016-04-22
TWI615150B (zh) 2018-02-21
EP2635255A1 (en) 2013-09-11
US20160243276A1 (en) 2016-08-25
CA2816576A1 (en) 2012-05-10
JP6026424B2 (ja) 2016-11-16
US20170035690A1 (en) 2017-02-09
US9333173B2 (en) 2016-05-10
TW201306867A (zh) 2013-02-16
AU2016259330A1 (en) 2016-12-08
US20120177695A1 (en) 2012-07-12
JP6189460B2 (ja) 2017-08-30
AU2016259330B2 (en) 2018-11-08
CN103282020B (zh) 2016-10-26
EP2635255B1 (en) 2019-08-21
CN104622789A (zh) 2015-05-20
JP2013541562A (ja) 2013-11-14
CN104622790A (zh) 2015-05-20
US11026885B2 (en) 2021-06-08
RU2640918C2 (ru) 2018-01-12
HK1210415A1 (en) 2016-04-22
CN103282020A (zh) 2013-09-04
CN104586742A (zh) 2015-05-06
CA2816576C (en) 2020-06-02

Similar Documents

Publication Publication Date Title
IN2013MN00758A (enExample)
GB2465677B (en) Non-systemic delivery of satiogens for use in the treatment of obesity and/or diabetes
EP4461326A3 (en) Flexible system for delivering an anchor
GB2471588A (en) Therapeutic peptidomimetic macrocycles
NZ707377A (en) Combination therapy methods for treating proliferative diseases
CY1119192T1 (el) Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα
EP3192526A3 (en) Exosomes for delivery of biotherapeutics
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
IL211952A0 (en) Implantable device for the delivery of risperidone and methods of use thereof
MX339125B (es) Endoprotesis de metal desnudo con receptaculos eluyentes de farmacos.
UA108885C2 (uk) Композиція рисперидону для ін'єкційної депо-форми
NZ606825A (en) Methods and compositions for treating complement-associated disorders
GB2458229B (en) Magnetic carrier and medical prepartion for controllable delivery and release of active substances
EP2406379A4 (en) COMPOSITIONS AND METHODS FOR RELEASING BIOLOGICALLY ACTIVE RNA
MX2013012458A (es) Suministro intravascular de composiciones de nanoparticulas y sus usos.
PT2210588E (pt) Composição expansível, essencialmente isenta de ingredientes farmaceuticamente activos para o tratamento da pele humana
PH12012501739A1 (en) Treatment of lupus nephritis using laquinimod
BR112013000841A2 (pt) composições farmacêuticas, métodos de tratamento da obesidade e distúrbios metabólicos relacionados, de redução da massa corpórea de mamífero, do crescimento da massa corpórea de mamífero, do consumo de comida em mamífero, de trtamento de paciente de adicção de substância psicoativa, de adicção de substância psicoativa e uso de forma ativada-potencializada de anticorpo para receptor de canabinoide humano.
WO2012037519A3 (en) Acceleration of wound healing by growth hormone releasing hormone and its agonists
MX340636B (es) Dispositivo oftalmico que tiene capacidad de liberacion de agentes terapeuticos y metodos para formar el mismo.
MA32568B1 (fr) Formulations pharmaceutiques contenant des ligands de recepteur de dopamine
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
IL210545A (en) Transplantation devices for use of octreotide transport and use of octreotide to create drugs
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
EP2866795A4 (en) POLYENOLZIN BINDER FOR THE ACTIVE PROMOTION OF THE INACTIVATION OF CANCER STRAIN CELLS AND FOR THE POTENTIATING OF CYTOTOXIC ANTITUMOROUS SUBSTANCES